Delving into the Latest Updates on Magnesium citrate with Synapse

Overview

Basic Info

SummaryMagnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio. It is approved for use in the exclusion of intestinal contents during colon examination and as a pretreatment laxative for abdominal surgery. Magnesium citrate is available under the trade names Magcorol and Tectlol. The drug is manufactured by RMJ Holdings and was first approved in Japan on April 28, 1973. Magnesium citrate works by attracting water to the intestine and promoting bowel movement, thus clearing the intestinal tract. It is commonly used for bowel preparation prior to colonoscopy or other medical procedures requiring a clear intestinal tract. Magnesium citrate is available over-the-counter as a liquid or tablet form,also used in the pill form as a magnesium dietary supplement.

Drug Type

Small molecule drug

Synonyms

Magnesium citrate (JAN/USP), Magnesium citrate (RMJ Holdings), Magnesium dicitrate

+ [6]

Target-

Mechanism-

Therapeutic Areas

Other DiseasesCardiovascular Diseases

Active Indication

Intestinal preparationEssential HypertensionHypertension

Inactive Indication-

Originator Organization

RMJ Holdings, Inc.

Active Organization

RMJ SGRpAHorii Pharmaceutical Ind., LTD.RMJ Holdings, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Apr 1973),

Intestinal preparation

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC6H8MgO7

InChIKeyROYPGAQNKYWYDI-UHFFFAOYSA-N

CAS Registry3344-18-1

View All Structures (2)

Author: Miyazaki, Haruka ; Fujisawa, Mizuho ; Takao, Madoka ; Kodama, Yuzo ; Takayama, Hiroshi ; Kinoshita, Masato ; Ueda, Chise ; Ikezawa, Nobuaki ; Toyonaga, Takashi ; Yoshizaki, Tetsuya ; Hori, Hitomi ; Hoki, Shinya ; Sakaguchi, Hiroya ; Morita, Yoshinori ; Abe, Hirofumi ; Ooi, Makoto ; Ishida, Ryosuke ; Okamoto, Norihiro ; Tanabe, Hiroshi ; Tanaka, Shinwa

BACKGROUND AND AIMSodium picosulfate plus magnesium citrate (SP + MC) is a well-tolerated bowel preparation agent. However, Japan currently approves only two methods of taking SP + MC: the day-before and split-dose preparation, without approval of same-day preparations. This study aimed to evaluate the efficacy and safety of same-day SP + MC preparations.METHODSThis was a multicenter, single-arm, nonrandomized, open-label study. We enrolled 145 Japanese patients between June and December 2023. The patients received two sachets of SP + MC dissolved in 300 ml of water and 1200 mL or more of clear liquid on the day of colonoscopy. Bowel cleansing efficacy, adverse events (AEs), and patient satisfaction were evaluated.RESULTSOf the enrolled patients, 137 underwent colonoscopy according to our protocol. Bowel preparation was adequate in 133 patients (97.1%). The mean total Boston Bowel Preparation Score was 8.3 ± 1.2. Five patients experienced AEs (3.6%): two (1.5%), abdominal pain; one (0.73%), ischemic enteritis; one (0.73%), vomiting or nausea; and one (0.73%), headache. All AEs were treated conservatively. None of the patients exhibited abnormal blood test results or clinical symptoms after receiving SP + MC. Regarding patient satisfaction, all patients were able to take SP + MC as directed; 136 (99.2%) expressed a preference for this bowel preparation for future colonoscopies.CONCLUSIONThe same-day SP + MC preparation showed high bowel-cleansing efficacy and satisfaction in Japanese patients without serious AEs.

01 Jun 2024·Therapeutic Apheresis and Dialysis

Meta‐analysis of regional citrate versus heparin anticoagulation for continuous renal replacement therapy

Letter

Author: Volbeda, Meint ; Franssen, Casper F M

31 May 2024·The International journal of oral & maxillofacial implants

Efficacy of Oral Magnesium on Bone Regeneration and Implant Stability in Immediate Dental Implants: A Randomized Controlled Trial.

Article

Author: Somvanshi, Shradha ; Rajanna, Harshitha ; Pandey, Akhilesh Kumar ; Chaudhry, Kirti ; Kumar, Pravin ; Singh, Surjit ; Chugh, Ankita

PURPOSEThe successful osseointegration around immediate implants requires high quality and quantity of osteogenesis around them. The role of magnesium as a boneenhancing mineral, and as an adjunctive analgesic has been well documented in orthopedic literature. However, there is a paucity of literature in its role in successful osseointegration around immediate implants. This randomized controlled trial sought to assess the promising impact of magnesium on osseointegration by examining various aspects of implant stability, correlating them with serum bone markers, and establishing a foundation for future research on its potential as a potent analgesic.MATERIALS AND METHODSImmediate implant placement was done after the extraction of the indicated mandibular molar tooth, and all the patients were segregated into 2 groups (Placebo- Lactose, and Magnesium citrate). Bone regenerate in the peri-implant area was assessed radiographically immediate post-operatively, on the 6th week and 12 weeks. Implant stability was measured immediate post-operatively, at the 4th week and 12th week. Serum parameters were procured pre-operatively and post-operatively for serum calcium, serum alkaline phosphatase (ALP), and serum parathyroid hormone at the 8th week, and serum vitamin D3 levels preoperatively.RESULTS54 immediate implants placed showed the demographics and baseline serum, clinical, and radiographic parameters were comparable in both groups. Analysis of Implant Stability Quotient at 12th week showed statistically significant difference in intervention group both on intergroup and intragroup analysis. Radiodensity measurement showed a statistically significant difference in both intragroup and intergroup analysis in the intervention group at the 6th and 12th week. In bone gap analysis, the difference in mean change in the horizontal bone gap (HG) at 6 weeks was non-significant while the difference in HG at the 12th week was significant in the intervention group. On intragroup analysis, mean change HG at 6 weeks and 12 weeks both were significant only in intervention group. Intergroup analysis of vertical bone gap (VG) 12 and VG 12-0 (mean difference in the vertical bone gap from 12th week-day 0) showed a statistically significant difference in the intervention group. On intragroup analysis, VG 12 was significantly better in the intervention group. On serum analysis, ALP post-operatively was found to be significantly raised (P=0.013) in intervention group. Numerical rating Scale (NRS) analysis showed a significant decrease in post-op day 5 and 7, (P=0.017) and (P=0.002) respectively.CONCLUSIONThe oral magnesium citrate supplementation after immediate implant placement helps in enhancing the stability of the immediate implants, along with improved radiodensity around them which was found to be statistically significant. It also helps in reducing the horizontal, and vertical gap around the implant and has significant analgesic potential.

100 Deals associated with Magnesium citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03265	Magnesium citrate	-	DB11110

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Intestinal preparation	JP	Horii Pharmaceutical Ind., LTD.	28 Apr 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 3	JP	RMJ Holdings, Inc.	30 Jan 2022
Hypertension	Phase 2	-	RMJ SGRpA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02977286 (CTgov)	Phase 4	Constipation	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Naloxegol Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	hwrgctdxjq(uignjiqier) = zzjtlvvdlf pfxfaplwek (jfwfcwhjjy, wrfpcvwqci - fkkvruxdzl) View more	-	16 Feb 2023
NCT02977286 (CTgov)	Phase 4	Constipation	12	Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	hwrgctdxjq(uignjiqier) = ajfdbdxtxl pfxfaplwek (jfwfcwhjjy, hdpovhcyve - rretpznvvj) View more	-	16 Feb 2023
WCN2015	Not Applicable	Diabetes Mellitus, Type 2	100	Magnesium dicitrate	bqvrrwrodp(nnhpvabcbw) = fnzwzegnhq murnjxbzkl (wfyekfedpd )	-	15 Oct 2015